Prevalence and risk factors of hepatitis A among blood donors in Qazvin, central Iran

被引:0
作者
Ramezani, H. [2 ]
Bozorgi, S. H. [2 ]
Nooranipour, M. [1 ]
Mostajeri, A. [2 ]
Kargar-Fard, H. [2 ]
Molaverdikhani, S. [2 ]
Mazdaki, A. [2 ]
Alavian, S. M. [1 ]
机构
[1] Baqiyatallah Hosp, Baqiyatallah Res Ctr Gastroenterol & Liver Dis, Tehran, Iran
[2] Iran Blood Transfus Org Res Ctr, Qazvin Blood Transfus Ctr, Qazvin, Iran
关键词
blood donors; hepatitis A virus; Iran; prevalence; risk factors; VIRUS-INFECTION; EPIDEMIOLOGY; CHILDREN; SEROPREVALENCE; VACCINATION;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The hepatitis A virus (HAV) is a major global health problem, especially in developing countries. Althrough children aged 5-14 years are the most infected age group, all age groups are equally affected in an HAV epidemic. The aim of this study was to determine the prevalence and related risk factors of HAV among blood donors in Qazvin, central Iran. Methods: A cross-sectional study was performed in April 2008 on a total of 351 blood donors aged 17 to 60 years. Information on demographic variables and probable risk factors was recorded. The blood samples were investigated for antibodies to HAV (HAV Ab). Data was analysed using the t-test, chi-square test and Fisher's exact test to examine the factors related to HAV Ab positivity. Results: Out of the 351 blood donors, 49.0 percent (n is 172) were regular blood donors, 94.0 percent (n is 330) were male and 71.0 percent (n is 248) were married. HAV Ab was found in 94.9 percent (n is 333) of the total sample. The prevalence of HAV Ab was higher among married and older participants. It was lower among those with a high school or vocational level of education (p is less than 0.05) than among those with a lower level of education. Conclusion: This study reveals a high prevalence of HAV Ab among adult blood donors in Qazvin, which indicates a high level of childhood contact with HAV in the area.
引用
收藏
页码:107 / 112
页数:6
相关论文
共 28 条
[1]  
Alavi Moghaddam M, 2005, HEPAT MON, V5, P145
[2]  
Alavian S -M. Iraq:., 2005, Hepatitis Monthly, V5, P53
[3]  
Alavian SM, 2008, HEPAT MON, V8, P281
[4]  
[Anonymous], 1996, MMWR Recomm Rep, V45, P1
[5]  
[Anonymous], HEP A, P1
[6]   Hepatitis A seroprevalence rate in Syria [J].
Antaki, N ;
Kebbewar, MK .
TROPICAL DOCTOR, 2000, 30 (02) :99-101
[7]   Comparison of immunogenicity of two hepatitis A vaccines -: VAQTA® and HAVRIX® -: in young adults [J].
Ashur, Y ;
Adler, R ;
Rowe, M ;
Shouval, D .
VACCINE, 1999, 17 (18) :2290-2296
[8]   Prevalence of anti-HAV and anti-HEV antibodies in Konya, Turkey [J].
Atabek, ME ;
Fyndyk, D ;
Gulyuz, A ;
Erkul, I .
HEALTH POLICY, 2004, 67 (03) :265-269
[9]  
Ataei Behrooz, 2008, Trop Gastroenterol, V29, P160
[10]  
Boyles S, 1996, VACCINE WKLY, V22, P14